Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0001427

Carvedilol

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol, BM-14190

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H26N2O4
Numéro CAS:
72956-09-3
Poids moléculaire :
406.47
Numéro MDL:
MFCD00864692
Code UNSPSC :
41116107
ID de substance PubChem :
329831422
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

carvedilol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC

InChI

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

Clé InChI

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Informations sur le gène

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRB1(153) , ADRB2(154) , ADRB3(155)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carvedilol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1096622

Carvedilol, United States Pharmacopeia (USP) Reference Standard

Y0000103

Carvedilol impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001426

Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard

1096644

Carvedilol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1096677

Carvedilol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1096633

Carvedilol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1096666

Carvedilol Related Compound D, United States Pharmacopeia (USP) Reference Standard

1096655

Carvedilol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1096688

Carvedilol System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

PHR2434

Carvedilol Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2435

Carvedilol Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2952

Carvedilol Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2953

Carvedilol Related Compound C, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazardEnvironment
GHS08,GHS09

Mention d'avertissement

Warning

Mentions de danger

H373,H411

Classification des risques

Aquatic Chronic 2 - STOT RE 2

Organes cibles

Liver,spleen,Uterus (including cervix),Adrenal gland

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Dhiraj Tripathi et al.
European journal of gastroenterology & hepatology, 22(8), 905-911 (2010-01-23)
Carvedilol is a potent noncardioselective beta-blocker, with weak vasodilating properties because of alpha 1 blockade. A reduction in both intrahepatic and portocollateral resistance contribute to enhanced effects on portal pressure. There are 10 published hemodynamic studies involving 168 patients investigating
Randall P Sharp et al.
The Annals of pharmacotherapy, 42(4), 564-571 (2008-03-28)
To examine the evidence regarding the impact of carvedilol on the serum lipid profile. Searches in MEDLINE and International Pharmaceutical Abstracts (1966-December 2007) were conducted. Search terms included carvedilol, cholesterol, lipids, hyperlipidemia, and beta-blockers. Published studies and case reports that
Gonçalo C Pereira et al.
Current pharmaceutical design, 17(20), 2113-2129 (2011-07-02)
Mitochondria have long been involved in several cellular processes beyond its role in energy production. The importance of this organelle for cardiac tissue homeostasis has been greatly investigated and its impairment can lead to cell death and consequent organ failure.
James J DiNicolantonio et al.
The American journal of cardiology, 113(3), 565-569 (2013-12-18)
A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica
Carol Chen-Scarabelli et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 12(6), 391-401 (2012-10-16)
β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique